x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
T2DM, which accounts for 90% of all diabetes, is a heterogeneous and progressive disease with a variety of causative and potentiating factors. The hyperglycemia of T2DM is often inadequately controlled, hence the need for a wider selection of glucose-lowering treatments. Ace Therapeutics can provide researchers engaged in drugs development of T2DM with more efficient function analysis and overall therapy services.
The glucose-lowing agents offered as alternatives to insulin injection include insulin analogs, sodium/glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase IV (DPP-IV) inhibitors. By increasing β-cell insulin secretion, delaying gastric emptying, and reducing glucagon secretion, glucagon-like peptide-1 (GLP-1) analogues successfully target and suppress post-prandial hyperglycinemia in T2DM. Metformin reduces hepatic glucose output, enhances peripheral tissue sensitivity, and stimulates GLP-1 secretion which is the first-line therapy of choice for patients with T2DM.
By modifying the peptide chain to change the biological and physicochemical characteristics of insulin, insulin analogs that are more suitable for human needs than traditional human insulin have been developed and can be used directly before meals, also known as mealtime insulin or fast-acting insulin.
The development of T2DM is a multifactorial and polygenic process, and its pathogenesis is complex. Most genes related to T2DM are related to β-cells function related. For example, FGF21 is a secreted secretion that can regulate glucose and lipid metabolism. Its biological activity mainly involves lowering blood glucose and improving blood lipid. GLP-1 acts on islet β-cells in the pancreas, promoting insulin secretion and at the same time promoting the proliferation and differentiation of islet β-cells.
Insulin Resistance and Pancreatic β-cell Dysfunction (Bailey, C. J.; et al. Br Med Bull. 2018.)
Insulin acts by binding to the insulin receptor (INSR) on the cell surface, a process that activates cell signaling. Antibodies can activate the INSR.
In humans, autoantibodies to the INSR typically bind at the insulin binding site. In most cases, these antibodies block insulin binding, causing severe insulin resistance and T2DM. The allosteric antibodies, antibodies that do not bind at the ligand binding site of receptors, can activate cell signaling.
Therapy research provides more options for diabetes treatment options. With the goal of scientific research of diabetes, Ace Therapeutics can provide a full set of therapy development services. Our services include but not limited to the followings.
Providing our clients with oral antidiabetics (including insulin analog) development services.
Providing antibody therapy services including discovering targets of T2DM therapeutic, developing and evaluating antibodies and developing allosteric antibodies to receptors.
Highly Customizable
One-stop Services
High Quality
Professional Team
Ace Therapeutics offers cost-effect and high-quality research services related to T2DM therapy for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us .
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
